NVAX

NVAX

USD

Novavax Inc. Common Stock

$7.510-0.175 (-2.277%)

Precio en Tiempo Real

Healthcare
Biotecnología
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$7.685

Máximo

$7.860

Mínimo

$7.500

Volumen

5.04M

Fundamentos de la Empresa

Capitalización de Mercado

1.2B

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

6.00M

Bolsa

NMS

Moneda

USD

Rango de 52 Semanas

Mínimo $5.01Actual $7.510Máximo $11.55

Noticias Relacionadas

Analyst Upgrades

TD Cowen Maintains Hold on Novavax, Lowers Price Target to $7

TD Cowen analyst Brendan Smith maintains Novavax with a Hold and lowers the price target from $8 to $7.

Ver más
TD Cowen Maintains Hold on Novavax, Lowers Price Target to $7
PR Newswire

Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment

Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid™ to Sanofi, enabling...

Ver más
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
Analyst Upgrades

Cantor Fitzgerald Initiates Coverage On Novavax with Overweight Rating, Announces Price Target of $18

Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on Novavax with a Overweight rating and announces Price Target of $18.

Ver más
Cantor Fitzgerald Initiates Coverage On Novavax with Overweight Rating, Announces Price Target of $18
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Novavax, Raises Price Target to $11

HC Wainwright & Co. analyst Sean Lee maintains Novavax with a Buy and raises the price target from $10 to $11.

Ver más
HC Wainwright & Co. Maintains Buy on Novavax, Raises Price Target to $11
PR Newswire

Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy

Novavax, Inc. (Nasdaq: NVAX) today announced that it has further executed against its planned transformation into a lean, agile operating model by...

Ver más
Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.